This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. A post hoc pooled analysis of 48-week data (n = 249) from the SUPREME study was performed. Assessments used were: Psoriasis Area Severity Index (PASI), Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A), and HADS - Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADS-A or HADS-D ≥ 11) were free of moderate to severe symptoms at weeks 16 and 48. Marked reductions in PASI and DLQI scores were observed over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS.

Talamonti, M., Malara, G., Natalini, Y., Bardazzi, F., Conti, A., Chiricozzi, A., et al. (2021). Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study. ACTA DERMATO-VENEREOLOGICA, 101 [10.2340/00015555-3712].

Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study

M Talamonti;
2021-01-01

Abstract

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. A post hoc pooled analysis of 48-week data (n = 249) from the SUPREME study was performed. Assessments used were: Psoriasis Area Severity Index (PASI), Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A), and HADS - Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADS-A or HADS-D ≥ 11) were free of moderate to severe symptoms at weeks 16 and 48. Marked reductions in PASI and DLQI scores were observed over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35
English
Con Impact Factor ISI
depression; psoriasis; quality of life; secukinumab; anxiety
Talamonti, M., Malara, G., Natalini, Y., Bardazzi, F., Conti, A., Chiricozzi, A., et al. (2021). Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study. ACTA DERMATO-VENEREOLOGICA, 101 [10.2340/00015555-3712].
Talamonti, M; Malara, G; Natalini, Y; Bardazzi, F; Conti, A; Chiricozzi, A; Mugheddu, C; Gisondi, P; Piaserico, S; Pagnanelli, G; Amerio, P; Potenza, C; Cantoresi, F; Concetta Fargnoli, M; Balato, A; Loconsole, F; Offidani, A; Bonifati, C; Prignano, F; Bartezaghi, M; Rausa, A; Aloisi, E; Orsenigo, R; Costanzo, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/260569
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact